신장암 진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Kidney Cancer Diagnostics Market - Scope of Report

TMR's report on the global kidney cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kidney cancer diagnostics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kidney cancer diagnostics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the kidney cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kidney cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kidney cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kidney cancer diagnostics market.

The report delves into the competitive landscape of the global kidney cancer diagnostics market. Key players operating in the global kidney cancer diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kidney cancer diagnostics market profiled in this report.

Key Questions Answered in Global kidney cancer diagnostics Market Report:

• What is the sales/revenue generated by kidney cancer diagnostics across all regions during the forecast period?
• What are the opportunities in the global kidney cancer diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Kidney Cancer Diagnostics Market - Research Objectives and Research Approach

The comprehensive report on the global kidney cancer diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kidney cancer diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kidney cancer diagnostics market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Kidney Cancer Diagnostics Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution / Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Kidney Cancer Diagnostics Market Analysis and Forecast, 2020-2034

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Product Type

• 6.1. Introduction and Definitions
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Product Type, 2020-2034
  • 6.3.1. Platform-based Products
  • 6.3.2. Instrument-based Products
  • 6.3.3. Kits and Reagents
  • 6.3.4. Others (Consumables, etc.)
• 6.4. Market Attractiveness, by Product Type

7. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Test Type

• 7.1. Introduction and Definitions
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Test Type, 2020-2034
  • 7.3.1. Biopsy
  • 7.3.2. Imaging Tests
  • 7.3.3. Blood Tests
  • 7.3.4. Others (Genetic Testing, etc.)
• 7.4. Market Attractiveness, by Test Type

8. Global Kidney Cancer Diagnostics Market Analysis and Forecast, By Cancer Stage

• 8.1. Introduction and Definitions
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, By Cancer Stage, 2020-2034
  • 8.3.1. Stage 1
  • 8.3.2. Stage 2
  • 8.3.3. Stage 3
  • 8.3.4. Stage 4
• 8.4. Market Attractiveness, By Cancer Stage

9. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Tumor Type

• 9.1. Introduction and Definitions
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Tumor Type, 2020-2034
  • 9.3.1. Renal Cell Carcinoma
  • 9.3.2. Clear Cell Carcinoma
  • 9.3.3. Non-clear Cell Carcinoma
• 9.4. Market Attractiveness, by Tumor Type

10. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Technology

• 10.1. Introduction and Definitions
• 10.2. Key Findings/Developments
• 10.3. Market Value Forecast, by Tumor Type, 2020-2034
  • 10.3.1. Fluorescent In Situ Hybridization
  • 10.3.2. Next Generation Sequencing
  • 10.3.3. Fluoroimmunoassay
  • 10.3.4. Comparative Genomic Hybridization
  • 10.3.5. Others (Immunohistochemical, etc.)
• 10.4. Market Attractiveness, by Tumor Type

11. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by End-user

• 11.1. Introduction and Definitions
• 11.2. Key Findings/Developments
• 11.3. Market Value Forecast, by End-user, 2020-2034
  • 11.3.1. Hospitals
  • 11.3.2. Cancer Research Centers
  • 11.3.3. Oncology Clinics
  • 11.3.4. Diagnostic Centers
  • 11.3.5. Ambulatory Surgery Centers
  • 11.3.6. Others (Research Institutes, etc.)
• 11.4. Market Attractiveness, by End-user

12. Global Kidney Cancer Diagnostics Market Analysis and Forecast, by Region

• 12.1. Key Findings
• 12.2. Market Value Forecast, by Region, 2020-2034
  • 12.2.1. North America
  • 12.2.2. Europe
  • 12.2.3. Asia Pacific
  • 12.2.4. Latin America
  • 12.2.5. Middle East & Africa
• 12.3. Market Attractiveness, by Region

13. North America Kidney Cancer Diagnostics Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Product Type, 2020-2034
  • 13.2.1. Platform-based Products
  • 13.2.2. Instrument-based Products
  • 13.2.3. Kits and Reagents
  • 13.2.4. Others (Consumables, etc.)
• 13.3. Market Attractiveness, by Product Type
• 13.4. Market Value Forecast, by Test Type, 2020-2034
  • 13.4.1. Biopsy
  • 13.4.2. Imaging Tests
  • 13.4.3. Blood Tests
  • 13.4.4. Others (Genetic Testing, etc.)
• 13.5. Market Attractiveness, by Test Type
• 13.6. Market Value Forecast, By Cancer Stage, 2020-2034
  • 13.6.1. Stage 1
  • 13.6.2. Stage 2
  • 13.6.3. Stage 3
  • 13.6.4. Stage 4
• 13.7. Market Attractiveness, By Cancer Stage
• 13.8. Market Value Forecast, by Tumor Type, 2020-2034
  • 13.8.1. Renal Cell Carcinoma
  • 13.8.2. Clear Cell Carcinoma
  • 13.8.3. Non-clear Cell Carcinoma
• 13.9. Market Attractiveness, by Tumor Type
• 13.10. Market Value Forecast, by Technology 2020-2034
  • 13.10.1. Fluorescent In Situ Hybridization
  • 13.10.2. Next Generation Sequencing
  • 13.10.3. Fluoroimmunoassay
  • 13.10.4. Comparative Genomic Hybridization
  • 13.10.5. Others (Immunohistochemical, etc.)
• 13.11. Market Attractiveness, by Technology
• 13.12. Market Value Forecast, by End-user, 2020-2034
  • 13.12.1. Hospitals
  • 13.12.2. Cancer Research Centers
  • 13.12.3. Oncology Clinics
  • 13.12.4. Diagnostic Centers
  • 13.12.5. Ambulatory Surgery Centers
  • 13.12.6. Others (Research Institutes, etc.)
• 13.13. Market Attractiveness, by End-user
• 13.14. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 13.14.1. U.S.
  • 13.14.2. Canada
• 13.15. Market Attractiveness Analysis
  • 13.15.1. By Product Type
  • 13.15.2. By Test Type
  • 13.15.3. By Cancer Stage
  • 13.15.4. By Tumor Type
  • 13.15.5. By End-user
  • 13.15.6. By Country

14. Europe Kidney Cancer Diagnostics Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Product Type, 2020-2034
  • 14.2.1. Platform-based Products
  • 14.2.2. Instrument-based Products
  • 14.2.3. Kits and Reagents
  • 14.2.4. Others (Consumables, etc.)
• 14.3. Market Attractiveness, by Product Type
• 14.4. Market Value Forecast, by Test Type, 2020-2034
  • 14.4.1. Biopsy
  • 14.4.2. Imaging Tests
  • 14.4.3. Blood Tests
  • 14.4.4. Others (Genetic Testing, etc.)
• 14.5. Market Attractiveness, by Test Type
• 14.6. Market Value Forecast, By Cancer Stage, 2020-2034
  • 14.6.1. Stage 1
  • 14.6.2. Stage 2
  • 14.6.3. Stage 3
  • 14.6.4. Stage 4
• 14.7. Market Attractiveness, By Cancer Stage
• 14.8. Market Value Forecast, by Tumor Type, 2020-2034
  • 14.8.1. Renal Cell Carcinoma
  • 14.8.2. Clear Cell Carcinoma
  • 14.8.3. Non-clear Cell Carcinoma
• 14.9. Market Attractiveness, by Tumor Type
• 14.10. Market Value Forecast, by Technology, 2020-2034
  • 14.10.1. Fluorescent In Situ Hybridization
  • 14.10.2. Next Generation Sequencing
  • 14.10.3. Fluoroimmunoassay
  • 14.10.4. Comparative Genomic Hybridization
  • 14.10.5. Others (Immunohistochemical, etc.)
• 14.11. Market Attractiveness, by Technology
• 14.12. Market Value Forecast, by End-user, 2020-2034
  • 14.12.1. Hospitals
  • 14.12.2. Cancer Research Centers
  • 14.12.3. Oncology Clinics
  • 14.12.4. Diagnostic Centers
  • 14.12.5. Ambulatory Surgery Centers
  • 14.12.6. Others (Research Institutes, etc.)
• 14.13. Market Attractiveness, by End-user
• 14.14. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 14.14.1. Germany
  • 14.14.2. U.K.
  • 14.14.3. France
  • 14.14.4. Italy
  • 14.14.5. Spain
  • 14.14.6. Rest of Europe
• 14.15. Market Attractiveness Analysis
  • 14.15.1. By Product Type
  • 14.15.2. By Test Type
  • 14.15.3. By Cancer Stage
  • 14.15.4. By Tumor Type
  • 14.15.5. By End-user
  • 14.15.6. By Country/Sub-region

15. Asia Pacific Kidney Cancer Diagnostics Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Product Type, 2020-2034
  • 15.2.1. Platform-based Products
  • 15.2.2. Instrument-based Products
  • 15.2.3. Kits and Reagents
  • 15.2.4. Others (Consumables, etc.)
• 15.3. Market Attractiveness, by Product Type
• 15.4. Market Value Forecast, by Test Type, 2020-2034
  • 15.4.1. Biopsy
  • 15.4.2. Imaging Tests
  • 15.4.3. Blood Tests
  • 15.4.4. Others (Genetic Testing, etc.)
• 15.5. Market Attractiveness, by Test Type
• 15.6. Market Value Forecast, By Cancer Stage, 2020-2034
  • 15.6.1. Stage 1
  • 15.6.2. Stage 2
  • 15.6.3. Stage 3
  • 15.6.4. Stage 4
• 15.7. Market Attractiveness, By Cancer Stage
• 15.8. Market Value Forecast, by Tumor Type, 2020-2034
  • 15.8.1. Renal Cell Carcinoma
  • 15.8.2. Clear Cell Carcinoma
  • 15.8.3. Non-clear Cell Carcinoma
• 15.9. Market Attractiveness, by Tumor Type
• 15.10. Market Value Forecast, by Technology 2020-2034
  • 15.10.1. Fluorescent In Situ Hybridization
  • 15.10.2. Next Generation Sequencing
  • 15.10.3. Fluoroimmunoassay
  • 15.10.4. Comparative Genomic Hybridization
  • 15.10.5. Others (Immunohistochemical, etc.)
• 15.11. Market Attractiveness, by Technology
• 15.12. Market Value Forecast, by End-user, 2020-2034
  • 15.12.1. Hospitals
  • 15.12.2. Cancer Research Centers
  • 15.12.3. Oncology Clinics
  • 15.12.4. Diagnostic Centers
  • 15.12.5. Ambulatory Surgery Centers
  • 15.12.6. Others (Research Institutes, etc.)
• 15.13. Market Attractiveness, by End-user
• 15.14. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 15.14.1. China
  • 15.14.2. Japan
  • 15.14.3. India
  • 15.14.4. Australia & New Zealand
  • 15.14.5. Rest of Asia Pacific
• 15.15. Market Attractiveness Analysis
  • 15.15.1. By Product Type
  • 15.15.2. By Test Type
  • 15.15.3. By Cancer Stage
  • 15.15.4. By Tumor Type
  • 15.15.5. By End-user
  • 15.15.6. By Country/Sub-region

16. Latin America Kidney Cancer Diagnostics Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast, by Product Type, 2020-2034
  • 16.2.1. Platform-based Products
  • 16.2.2. Instrument-based Products
  • 16.2.3. Kits and Reagents
  • 16.2.4. Others (Consumables, etc.)
• 16.3. Market Attractiveness, by Product Type
• 16.4. Market Value Forecast, by Test Type, 2020-2034
  • 16.4.1. Biopsy
  • 16.4.2. Imaging Tests
  • 16.4.3. Blood Tests
  • 16.4.4. Others (Genetic Testing, etc.)
• 16.5. Market Attractiveness, by Test Type
• 16.6. Market Value Forecast, By Cancer Stage, 2020-2034
  • 16.6.1. Stage 1
  • 16.6.2. Stage 2
  • 16.6.3. Stage 3
  • 16.6.4. Stage 4
• 16.7. Market Attractiveness, By Cancer Stage
• 16.8. Market Value Forecast, by Tumor Type, 2020-2034
  • 16.8.1. Renal Cell Carcinoma
  • 16.8.2. Clear Cell Carcinoma
  • 16.8.3. Non-clear Cell Carcinoma
• 16.9. Market Attractiveness, by Tumor Type
• 16.10. Market Value Forecast, by Technology, 2020-2034
  • 16.10.1. Fluorescent In Situ Hybridization
  • 16.10.2. Next Generation Sequencing
  • 16.10.3. Fluoroimmunoassay
  • 16.10.4. Comparative Genomic Hybridization
  • 16.10.5. Others (Immunohistochemical, etc.)
• 16.11. Market Attractiveness, by Technology
• 16.12. Market Value Forecast, by End-user, 2020-2034
  • 16.12.1. Hospitals
  • 16.12.2. Cancer Research Centers
  • 16.12.3. Oncology Clinics
  • 16.12.4. Diagnostic Centers
  • 16.12.5. Ambulatory Surgery Centers
  • 16.12.6. Others (Research Institutes, etc.)
• 16.13. Market Attractiveness, by End-user
• 16.14. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 16.14.1. Brazil
  • 16.14.2. Mexico
  • 16.14.3. Rest of Latin America
• 16.15. Market Attractiveness Analysis
  • 16.15.1. By Product Type
  • 16.15.2. By Test Type
  • 16.15.3. By Cancer Stage
  • 16.15.4. By Tumor Type
  • 16.15.5. By End-user
  • 16.15.6. By Country/Sub-region

17. Middle East & Africa Kidney Cancer Diagnostics Market Analysis and Forecast

• 17.1. Introduction
  • 17.1.1. Key Findings
• 17.2. Market Value Forecast, by Product Type, 2020-2034
  • 17.2.1. Platform-based Products
  • 17.2.2. Instrument-based Products
  • 17.2.3. Kits and Reagents
  • 17.2.4. Others (Consumables, etc.)
• 17.3. Market Attractiveness, by Product Type
• 17.4. Market Value Forecast, by Test Type, 2020-2034
  • 17.4.1. Biopsy
  • 17.4.2. Imaging Tests
  • 17.4.3. Blood Tests
  • 17.4.4. Others (Genetic Testing, etc.)
• 17.5. Market Attractiveness, by Test Type
• 17.6. Market Value Forecast, By Cancer Stage, 2020-2034
  • 17.6.1. Stage 1
  • 17.6.2. Stage 2
  • 17.6.3. Stage 3
  • 17.6.4. Stage 4
• 17.7. Market Attractiveness, By Cancer Stage
• 17.8. Market Value Forecast, by Tumor Type, 2020-2034
  • 17.8.1. Renal Cell Carcinoma
  • 17.8.2. Clear Cell Carcinoma
  • 17.8.3. Non-clear Cell Carcinoma
• 17.9. Market Attractiveness, by Tumor Type
• 17.10. Market Value Forecast, by Technology, 2020-2034
  • 17.10.1. Fluorescent In Situ Hybridization
  • 17.10.2. Next Generation Sequencing
  • 17.10.3. Fluoroimmunoassay
  • 17.10.4. Comparative Genomic Hybridization
  • 17.10.5. Others (Immunohistochemical, etc.)
• 17.11. Market Attractiveness, by Technology
• 17.12. Market Value Forecast, by End-user, 2020-2034
  • 17.12.1. Hospitals
  • 17.12.2. Ambulatory Surgical Centers
  • 17.12.3. Nursing Centers
  • 17.12.4. Others (Long Term Care Centers, etc.)
• 17.13. Market Attractiveness, by End-user
• 17.14. Market Value Forecast, by Country/Sub-region, 2020-2034
  • 17.14.1. GCC Countries
  • 17.14.2. South Africa
  • 17.14.3. Rest of Middle East & Africa
• 17.15. Market Attractiveness Analysis
  • 17.15.1. By Product Type
  • 17.15.2. By Test Type
  • 17.15.3. By Cancer Stage
  • 17.15.4. By Tumor Type
  • 17.15.5. By End-user
  • 17.15.6. By Country/Sub-region

18. Competition Landscape

• 18.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 18.2. Market Share Analysis, by Company (2023)
• 18.3. Company Profiles
  • 18.3.1. Siemens Healthineers
    • 18.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.1.2. Product Portfolio
    • 18.3.1.3. Financial Overview
    • 18.3.1.4. SWOT Analysis
    • 18.3.1.5. Strategic Overview
  • 18.3.2. Koninklijke Philips N.V.
    • 18.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.2.2. Product Portfolio
    • 18.3.2.3. Financial Overview
    • 18.3.2.4. SWOT Analysis
    • 18.3.2.5. Strategic Overview
  • 18.3.3. FUJIFILM Holdings Corporation
    • 18.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.3.2. Product Portfolio
    • 18.3.3.3. Financial Overview
    • 18.3.3.4. SWOT Analysis
    • 18.3.3.5. Strategic Overview
  • 18.3.4. Grail
    • 18.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.4.2. Product Portfolio
    • 18.3.4.3. Financial Overview
    • 18.3.4.4. SWOT Analysis
    • 18.3.4.5. Strategic Overview
  • 18.3.5. Laboratory Corporation of America Holdings
    • 18.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.5.2. Product Portfolio
    • 18.3.5.3. Financial Overview
    • 18.3.5.4. SWOT Analysis
  • 18.3.6. Thermo Fisher Scientific
    • 18.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.6.2. Product Portfolio
    • 18.3.6.3. Financial Overview
    • 18.3.6.4. SWOT Analysis
    • 18.3.6.5. Strategic Overview
  • 18.3.7. Myriad Genetics, Inc.
    • 18.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.7.2. Product Portfolio
    • 18.3.7.3. Financial Overview
    • 18.3.7.4. SWOT Analysis
    • 18.3.7.5. Strategic Overview
  • 18.3.8. Canon Medical Systems Corporation
    • 18.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.8.2. Product Portfolio
    • 18.3.8.3. Financial Overview
    • 18.3.8.4. SWOT Analysis
    • 18.3.8.5. Strategic Overview
  • 18.3.9. QIAGEN N.V.
    • 18.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.9.2. Product Portfolio
    • 18.3.9.3. Financial Overview
    • 18.3.9.4. SWOT Analysis
    • 18.3.9.5. Strategic Overview
  • 18.3.10. Illumina, Inc.
    • 18.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.10.2. Product Portfolio
    • 18.3.10.3. Financial Overview
    • 18.3.10.4. SWOT Analysis
    • 18.3.10.5. Strategic Overview
  • 18.3.11. Ambry Genetics
    • 18.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.11.2. Product Portfolio
    • 18.3.11.3. Financial Overview
    • 18.3.11.4. SWOT Analysis
    • 18.3.11.5. Strategic Overview
  • 18.3.12. Invitae Corp.
    • 18.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.12.2. Product Portfolio
    • 18.3.12.3. Financial Overview
    • 18.3.12.4. SWOT Analysis
    • 18.3.12.5. Strategic Overview
  • 18.3.13. Centogene N.V.
    • 18.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
    • 18.3.13.2. Product Portfolio
    • 18.3.13.3. Financial Overview
    • 18.3.13.4. SWOT Analysis
    • 18.3.13.5. Strategic Overview